Use of the CCR2/CCR5 antagonist, Cenicriviroc (CVC) has been shown to have potent anti-inflammatory effects in mice and is currently being evaluated in a phase 2b clinical trial in patients with NASH and fibrosis[10]. The gene discussed is CCR5; the disease is metabolic dysfunction-associated steatohepatitis.